Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02567942

Enrollment

153

Registered

2015-10-05

Start date

2016-02-29

Completion date

2018-04-30

Last updated

2021-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Brief summary

Anesthetics agents has variety inflammation during the cancer surgery. This perioperative inflammation can influence to cancer metastasis or recurrence. The purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

Detailed description

The patients were allocated randomly to receive propofol or sevoflurane. Also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order. 1. immediate before anesthesia induction 2. postoperative 1 hours 3. postoperative 24 hours Serum in blood will be obtained and activity of helper T cell, natural killer cell and level of serum cytokine will be evaluated by flow cytometry or enzyme-linked immunosorbent assay

Interventions

DRUGsevoflurane group

Patient will be anesthetized by using sevoflurane inhalation during operation

DRUGpropofol group

Patient will be anesthetized by using propofol infusion during operation

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient who was planned to undergo colon cancer surgery.

Exclusion criteria

* age \< 20 years old * history of hypersensitivity reaction in propofol or sevoflurane * history of previous cancer * patient with ongoing inflammation

Design outcomes

Primary

Measure	Time frame	Description
natural killer cell activity	preoperative time. postoperative 1 hours and 24 hours	change of percentage of natural killer cell (scores range from 0 to 100)

Secondary

Measure	Time frame	Description
helper T cell activity	preoperative time. postoperative 1 hours and 24 hours	change of percentage of helper T cell (scores range from 0 to 100)

Other

Measure	Time frame	Description
change of percentage of CD39 and CD73	preoperative time. postoperative 1 hours and 24 hours	change of percentage of CD39 and CD73 (scores range from 0 to 100)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026